MDEA

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Retrieved on: 
Friday, May 26, 2023
MDAI, Therapy, MEAI, PTSD, PCT, MDE, Literature, Patent, Post-traumatic stress disorder, Patient, USE, MBDB, Empathy, Terran, SALTS, MDMA, MDEA, Pharmaceutical industry

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.

Key Points: 
  • MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
  • Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
  • As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
  • Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Retrieved on: 
Thursday, May 11, 2023
MDMC, REMS, MDAI, Depression, Therapy, MDEA, Mitigation, Methylone, Anxiety, Therapeutic index, Pathology, Pharmacokinetics, PCT, MDE, DSM-IV codes, Literature, OF, Patent, Patient, Post-traumatic stress disorder, USE, MBDB, Empathy, Salt, SALTS, MDMA, Safety, Pharmaceutical industry, Vaccine, Terran, PTSD

The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.

Key Points: 
  • The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
  • Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
  • Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
  • Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.

ASP Health and Planet Innovation Receive 2022 Medical Design Excellence Award

Retrieved on: 
Tuesday, May 10, 2022
Bronze Award, ROSE, PLANET, Health, ASC, Engineering, FNA, Physician, Patient, Patient safety, Anesthesia, HEALTH, Partnership, FDA, Cancer, Diagnosis, Hospital, Pressure, ASP, PI, American Society of Cytopathology, Marketing, Medtech, Society, MDEA, CEO, Technology, Research, AI, Collection, Risk, Medicine, Medical device, Pharmaceutical industry, Medical imaging, Cytopathology

EVANSTON, Ill. and IRVINE, Calif., May 10, 2022 /PRNewswire-PRWeb/ -- ASP Health, a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis, and Planet Innovation (PI), ASP Health's product development and commercialization partner, have received the Bronze Award in the Testing and Diagnostic Product and Systems category for their innovative, FDA-registered automated sample preparation system. The company introduced its novel system at the American Society of Cytopathology (ASC) 69th Annual Scientific Meeting in November 2021.

Key Points: 
  • The ASP Health platform was honored in the 2022 Medical Design Excellence Awards (MDEA), the premier awards program for the MedTech industry.
  • ABOUT ASP HEALTH ASP Health is a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis.
  • ASP Health partners with Planet Innovation , a world-class company known for creating breakthrough products and commercially successful businesses.
  • ABOUT PLANET INNOVATION Planet Innovation (PI) is a healthtech innovation and commercialization company that exists to create breakthrough products and commercially successful businesses that transform industries and have a positive impact on the world.

Smart-C, World's First Hyper-Portable Surgical Imaging System, Receives Prestigious Medical Device Design Award

Retrieved on: 
Monday, April 18, 2022
Medical Supplies, Health, Medical Devices, Hospitals, Surgery, General Health, Radiology, MDDI, Â, MDEA, Medtech, Medicine, Turner, Rain, Military medicine, Doctor of Philosophy, Engineering, Patient, COO, Efficiency, Review, Technology, Paola Lattus, Health care, Nursing, Multimedia, Industry, Business, Medical imaging, Imaging

The Smart-C, by Turner Imaging Systems, has received the 2022 Medical Design Excellence Awards (MDEA) Silver Medal in the category of Radiological, Imaging, and Electromechanical Devices.

Key Points: 
  • The Smart-C, by Turner Imaging Systems, has received the 2022 Medical Design Excellence Awards (MDEA) Silver Medal in the category of Radiological, Imaging, and Electromechanical Devices.
  • This is the medtech industrys premier award program to honor achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
  • Healthcare systems are under enormous strain and the novel Smart-C design challenges the choke-point of traditional diagnostic and surgical imaging.
  • ABOUT TURNER IMAGING SYSTEMS: Turner Imaging Systems develops and markets X-ray imaging systems that give the user the ability to acquire X-ray images wherever and whenever they are needed.

Kleiner Device Labs' KG2 Surge Flow-Thru Interbody System Awarded Bronze in the 2022 Medical Design Excellence Awards

Retrieved on: 
Wednesday, April 13, 2022
CEO, MDEA, MD, Work, Medicine, KG2, Implant, PLIF, FDA, Industry, Cannula, Genesis Revisited II, Medical device, Antibiotics

The annual MDEA competition recognizes products that are moving the $450 billion medical device industry forward through live-saving innovations and remarkable technological advancements.  The MDEAs are determined each year by an independent panel--clinicians, engineers and designers—to select finalists as well as winners in each of 10 product categories. 

Key Points: 
  • INCLINE VILLAGE, Nev., April 13, 2022 /PRNewswire/ -- Kleiner Device Labs today announced that its new KG2Surgeflow-thru interbody system was recognized with the Bronze award in the 2022 Medical Design Excellence Awards (MDEA) in the Implant and Tissue-Replacement Products category.
  • The KG2 system maximizes total bone graft delivery volume and streamlines TLIF and PLIF spinal fusion procedures.
  • The FDA-cleared KG2 Surge system streamlines the implant delivery and grafting steps in lumbar spinal fusion procedures.
  • Kleiner Device Labs is creating new instruments and devices to advance minimally invasive spine surgery and improve outcomes and costs.

OrthoPediatrics Spotlights Award-Winning ApiFix® Technology at IMAST

Retrieved on: 
Tuesday, April 12, 2022
Health, Elective surgery, CE marking, MDEA, Adult, Adolescence, MD, Medicine, Plouézec International Meetings, Trauma, Scoliosis, GLOBE, Spine, Engineering, Patient, Surgeon, Technology, Company, AIS, Deformity, Orthopediatrics, FDA, Medical device, Pharmaceutical industry

WARSAW, Ind., April 12, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, showcased its award-winning technology, the ApiFix System, at the 2022 International Meeting on Advanced Spine Techniques (IMAST) held in Miami, Florida April 6-9, 2022.

Key Points: 
  • WARSAW, Ind., April 12, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, showcased its award-winning technology, the ApiFix System, at the 2022 International Meeting on Advanced Spine Techniques (IMAST) held in Miami, Florida April 6-9, 2022.
  • During the conference the Company conducted a hands-on workshop on its ApiFix procedure, a technology which offers a non-fusion alternative to adolescent idiopathic scoliosis surgery.
  • Concurrently on Thursday, April 7, ApiFix was named the Gold Winner of the 2022 Medical Design Excellence Awards (MDEA).
  • Winning the MDEA Gold Award for ApiFix exemplifies this commitment and demonstrates the hard work put forth by our international team.

PixCell's HemoScreen™ Takes Home Gold and Best-in-Show Awards in 2022 Medical Design Excellence Competition

Retrieved on: 
Tuesday, April 12, 2022
CBC, Method, Medicine, Lymphatic system, Viscoelasticity, City centre, AI, System, CEO, Gold, Anemia, Quality of life, Health, POC, Technology, MDEA, Machine learning, Solution, Complete blood count, Disease management, FDA, Blood, Engineering, Patient, Infection, Pharmaceutical industry, Medical device

YOKNEAM ILLIT, Israel, April 12, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced that HemoScreen™ was named a gold winner in the Testing and Diagnostic Products and Systems category in the 2022 Medical Design Excellence Awards (MDEA). In addition, HemoScreen™ was named the Best-in-Show winner, MDEA's top honor.

Key Points: 
  • YOKNEAM ILLIT,Israel, April 12, 2022 /PRNewswire/ -- PixCell Medical ,innovator of rapid hematology testing solutions at the point-of-care,today announced that HemoScreen was named a gold winner in the Testing and Diagnostic Products and Systems category in the 2022 Medical Design Excellence Awards (MDEA) .
  • MDEA, the medtech industry's premier awards program, honors significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
  • "This could have a positive impact on time-to-rescue considering quicker differential diagnosis can lead to quicker interventions.
  • The cost point compared to return-on-investment is attractive given the frequency of use and ability for those without med tech qualifications to process."

Seno Medical’s Imagio® Breast Imaging System Selected As GOLD Winner in Medical Device Excellence Awards

Retrieved on: 
Monday, April 11, 2022
Seno, Radiation, Hypoxia, X-ray, GOLD, Malignancy, Medicine, Adult, Breast, Certification, MDEA, Cancer, Radiology, Health, Artificial intelligence, Technology, Stavros S Niarchos, Google Images, GLOBE, Physician, Engineering, Patient, Medical imaging

San Antonio, TX, April 11, 2022 (GLOBE NEWSWIRE) -- The 2022 Medical Device Excellence Awards program has selected Seno Medicals Imagio Breast Imaging System as a GOLD award winner in the Radiological, Imaging, and Electromechanical Devices category.

Key Points: 
  • San Antonio, TX, April 11, 2022 (GLOBE NEWSWIRE) -- The 2022 Medical Device Excellence Awards program has selected Seno Medicals Imagio Breast Imaging System as a GOLD award winner in the Radiological, Imaging, and Electromechanical Devices category.
  • The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

OrthoPediatrics’ ApiFix® System Selected as 2022 MDEA Finalist

Retrieved on: 
Wednesday, April 6, 2022
Patent, Medicine, Nursing, Orthopediatrics, Safety, Review, Technology, Medtech, MDEA, Adolescence, GLOBE, Patient, Elective surgery, Pharmaceutical industry, Scoliosis

WARSAW, Indiana, April 06, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce that the ApiFix System has been named a category finalist for the 2022 Medical Design Excellence Awards (MDEA), the premier design awards program for the medical technology industry.

Key Points: 
  • WARSAW, Indiana, April 06, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce that the ApiFix System has been named a category finalist for the 2022 Medical Design Excellence Awards (MDEA), the premier design awards program for the medical technology industry.
  • Entries are judged by an impartial panel of MedTech experts, including practicing doctors, nurses, and technicians alongside industrial designers, engineers, manufacturers, and human factors experts.
  • We are delighted and honored to be named a finalist for MDEA, said Kimber Chang, Global Marketing Manager of Scoliosis for OrthoPediatrics.
  • The ApiFixprocedure offers select adolescent idiopathic scoliosis (AIS) patients a less invasive, motion-preserving option for achieving curve correction without the permanence of fusion.

ASSURE Wearable Cardioverter Defibrillator (WCD) System Earns 2022 Medical Design Excellence Award

Retrieved on: 
Monday, April 11, 2022
Health, Medical Devices, Cardiology, Arrest, Risk, Heart Rhythm, ICD, Medicine, Medical device, Multimedia, City, Contamination Indicator Decontamination Assurance System, Research, Food and Drug Administration, CEO, Heart Rhythm Society, Food, Industry, AED, Medtech, Photograph, MDEA, Health technology, WCD, Tactile, Arrhythmia, Engineering, Patient, Bain Capital

Kestra Medical Technologies announced today that the companys ASSURE Wearable Cardioverter Defibrillator (WCD) system was recognized as one of the winners of the 2022 Medical Design Excellence Awards (MDEA), garnering honors in the Cardiovascular Devices category.

Key Points: 
  • Kestra Medical Technologies announced today that the companys ASSURE Wearable Cardioverter Defibrillator (WCD) system was recognized as one of the winners of the 2022 Medical Design Excellence Awards (MDEA), garnering honors in the Cardiovascular Devices category.
  • View the full release here: https://www.businesswire.com/news/home/20220411005323/en/
    Kestra Medical Technologies announced today that the companys ASSURE Wearable Cardioverter Defibrillator (WCD) system was recognized as one of the winners of the 2022 Medical Design Excellence Awards (MDEA).
  • The ASSURE System represents the next generation of monitoring and therapy to protect patients at risk of sudden cardiac arrest.
  • (Photo credit: Kestra Medical Technologies)
    The ASSURE WCD system represents the next generation of monitoring and therapy to protect patients at risk of sudden cardiac arrest.